Soleno Therapeutics (SLNO) EBT Margin (2015 - 2026)
Soleno Therapeutics (SLNO) reported EBT Margin of 36.9% for Q1 2026, down 21.92% on a QoQ basis from 47.27% in Q4 2025.
Soleno Therapeutics (SLNO) has 5 years of EBT Margin data on file, last reported at 36.9% in Q1 2026.
- Quarterly EBT Margin changed N/A year-over-year to 36.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.94% (changed N/A YoY) and the FY2025 annual result came in at 10.97%, changed N/A from the prior year.
- EBT Margin declined to 36.9% in Q1 2026 per SLNO's latest filing, from 47.27% in the prior quarter.
- Across five years, EBT Margin topped out at 47.27% in Q4 2025 and bottomed at 14.42% in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 18.99% |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 36.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.90% |
| Dec 31, 2025 | 47.27% |
| Sep 30, 2025 | 39.40% |
| Jun 30, 2025 | -14.42% |
| Jun 30, 2017 | -296,500.00% |
| Mar 31, 2017 | -517.74% |
| Dec 31, 2016 | -126.35% |
| Sep 30, 2016 | -598.18% |
| Jun 30, 2016 | -114,750.00% |
| Mar 31, 2016 | -953.69% |
| Dec 31, 2015 | -4,742.81% |
| Sep 30, 2015 | -11,788.89% |
| Jun 30, 2015 | -3,138.14% |
| Mar 31, 2015 | -11,031.82% |